This company is no longer active
Eiger BioPharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Eiger BioPharmaceuticals's earnings have been declining at an average annual rate of -9.7%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been growing at an average rate of 59.9% per year.
Key information
-9.7%
Earnings growth rate
15.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 59.9% |
| Return on equity | n/a |
| Net Margin | -475.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues
Apr 01
The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%
Jan 04Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%
Dec 20Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher
Nov 09Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt
Oct 06Eiger sheds ~20% on abandonment of EUA request for COVID therapy
Oct 05Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy
Sep 06Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst
Jul 26European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy
Jul 20Revenue & Expenses Breakdown
How Eiger BioPharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 16 | -75 | 25 | 62 |
| 30 Sep 23 | 15 | -87 | 29 | 69 |
| 30 Jun 23 | 15 | -96 | 30 | 77 |
| 31 Mar 23 | 15 | -97 | 32 | 74 |
| 31 Dec 22 | 13 | -97 | 29 | 75 |
| 30 Sep 22 | 14 | -93 | 27 | 75 |
| 30 Jun 22 | 13 | -89 | 26 | 71 |
| 31 Mar 22 | 11 | -86 | 25 | 68 |
| 31 Dec 21 | 12 | -34 | 24 | 64 |
| 30 Sep 21 | 9 | -31 | 23 | 59 |
| 30 Jun 21 | 6 | -24 | 22 | 50 |
| 31 Mar 21 | 4 | -21 | 21 | 46 |
| 31 Dec 20 | 0 | -65 | 21 | 42 |
| 30 Sep 20 | 0 | -63 | 20 | 41 |
| 30 Jun 20 | 0 | -66 | 19 | 45 |
| 31 Mar 20 | 0 | -68 | 18 | 48 |
| 31 Dec 19 | 0 | -70 | 17 | 52 |
| 30 Sep 19 | 0 | -70 | 17 | 52 |
| 30 Jun 19 | 0 | -68 | 16 | 51 |
| 31 Mar 19 | 0 | -61 | 15 | 44 |
| 31 Dec 18 | 0 | -52 | 14 | 37 |
| 30 Sep 18 | 0 | -47 | 13 | 33 |
| 30 Jun 18 | 0 | -39 | 12 | 26 |
| 31 Mar 18 | 0 | -40 | 11 | 28 |
| 31 Dec 17 | 0 | -42 | 12 | 30 |
| 30 Sep 17 | 0 | -44 | 13 | 31 |
| 30 Jun 17 | 0 | -47 | 13 | 33 |
| 31 Mar 17 | 0 | -49 | 13 | 36 |
| 31 Dec 16 | 0 | -47 | 13 | 33 |
| 30 Sep 16 | 0 | -41 | 13 | 27 |
| 30 Jun 16 | 0 | -33 | 10 | 21 |
| 31 Mar 16 | 0 | -22 | 8 | 13 |
| 31 Dec 15 | 0 | -13 | 5 | 8 |
| 30 Sep 15 | 0 | -7 | 2 | 5 |
| 31 Dec 14 | 0 | -2 | 1 | 1 |
Quality Earnings: EIGR.Q is currently unprofitable.
Growing Profit Margin: EIGR.Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EIGR.Q is unprofitable, and losses have increased over the past 5 years at a rate of 9.7% per year.
Accelerating Growth: Unable to compare EIGR.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EIGR.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: EIGR.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.